# Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

> **NCT00295841** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 53 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** clofarabine
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT00295841
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2015-01-07
- **Final completion:** 2015-01-07
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295841, "Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00295841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*